Flt3L in Treating Patients With Metastatic Colorectal Cancer

Completed · Phase 1

Conditions studied: Colorectal Cancer, Metastatic Cancer

In brief

RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.

Key facts

Study ID

NCT00003431

Run by

Duke University

Starts

1998-06-01

Expected to finish

2001-05-01

Last updated by the study team

2013-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Duke Comprehensive Cancer Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.